Carbamic Acid

Carbamic Acid

SCHEMBL3748172

CC(C)(C)OC(=O)N1CCN(c2cc(F)cc(B3OC(C)(C)C(C)(C)O3)c2)CC1.NC(=O)O

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.43
LMNA P02545 2/20 0.43
ALDH1A1 P00352 1/20 0.43
GPR119 Q8TDV5 6/20 0.41
PDK2 Q15119 1/20 0.41
USP30 Q70CQ3 1/20 0.40
PIK3CA P42336 1/20 0.39
SMN1; SMN2 Q16637 4/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
CYP2C19 P33261 1/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
TSHR P16473 1/20 0.37
GBA1 P04062 1/20 0.36
ADAMTS5 Q9UNA0 1/20 0.36
NAMPT P43490 1/20 0.36
PARP14 Q460N5 1/20 0.36
KIT P10721 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3758659 0.96 MAPT (0.46) MAPTLMNAALDH1A1GPR119PDK2
SCHEMBL3748171 0.87 USP30 (0.37) MAPTLMNAALDH1A1GPR119PDK2
SCHEMBL3758304 0.83 ADAMTS5 (0.42) MAPTLMNASMN1; SMN2MEN1KMT2A
SCHEMBL15753879 0.82 MAPT (0.47) MAPTLMNAALDH1A1GPR119PDK2
SCHEMBL24847161 0.82 MAPT (0.44) MAPTLMNAALDH1A1GPR119PDK2
SCHEMBL30180017 0.82 MAPT (0.44) MAPTLMNAALDH1A1GPR119PDK2
SCHEMBL30179960 0.82 MAPT (0.44) MAPTLMNAALDH1A1GPR119PDK2
SCHEMBL26094144 0.82 MAPT (0.44) MAPTLMNAALDH1A1GPR119PDK2
SCHEMBL25167577 0.81 USP30 (0.43) MAPTLMNAALDH1A1GPR119PDK2
SCHEMBL3754452 0.81 EGLN2 (0.47) MAPTLMNAALDH1A1GPR119PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150232429-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE 2015-08-20 US disclosed
US-9018205-B2 Substituted pyrimidinyl-amines as protein kinase inhibitors THE SCRIPPS RESEARCH INSTITUTE (US) 2015-04-28 US disclosed
EP-2200436-B1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS SCRIPPS RESEARCH INST (US) 2015-01-21 EP disclosed
US-8530480-B2 Substituted pyrimidinyl-amines as protein kinase inhibitors THE SCRIPPS RESEARCH INSTITUTE (US) 2013-09-10 US disclosed
US-20130231336-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE (US) 2013-09-05 US disclosed
US-20100298312-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE (US) 2010-11-25 US disclosed
EP-2200436-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS The Scripps Research Institute (US) 2010-06-30 EP disclosed
WO-2009032861-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE (US) 2009-03-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130231336-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS MAP3K20, MAP3K5, MAP3K7 MAPT 1055/4885LMNA 3037/4885ALDH1A1 4097/4885
US-20100298312-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS MAP3K20, MAP3K5, MAP3K7 MAPT 1055/4885LMNA 3037/4885ALDH1A1 4097/4885
US-20150232429-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS MAP3K20, MAP3K5, MAP3K7 MAPT 1055/4885LMNA 3037/4885ALDH1A1 4097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.